Name: MarketsandMarkets ImmunoBio Series 2024 - West Coast Edition
Start: 2024-02-08
End: 2024-02-09
Location: Double Tree by Hilton, San Diego - Mission Valley | 7450 Hazard Centre Drive San Diego, CA

WHAT TO EXPECT

CUTTING-EDGE INSIGHTS: Access the latest advancements in biomarker discovery, precision medicine, and clinical applications spanning cancer, immunology, neurodegenerative disorders, and cardiovascular biomarkers.
MULTIDISCIPLINARY LEARNING: Gain a comprehensive understanding of microbiome and probiotics research, exploring diverse topics and practical applications across healthcare, biotechnology, and food production.
INNOVATIVE IMMUNOTHERAPY: Dive into immune-oncology projects, exploring antibodies, cellular therapy, and immune checkpoint research. Contribute to interactive discussions, share your work, and stay updated on cutting-edge technologies and platforms.
PROFESSIONAL DEVELOPMENT: Enhance your skills with workshops on biomarker data analysis, machine learning, and artificial intelligence applications. Learn best practices and methodologies for microbiome and probiotics research.
PRACTICAL APPLICATIONS: Discover how research translates into real-world applications. Explore exhibitor showcases, demonstrations, and case studies, gaining insights into the latest tools and technologies.
PERSONAL AND INDUSTRY GROWTH: Step out of your comfort zone, engage in interactive roundtables, and contribute to key discussions. Elevate your personal and professional growth within the dynamic fields of biomarker research, microbiome studies, and immunotherapy.

Immerse yourself in groundbreaking research, expand your network, and drive innovation at the Immunobio Series, where science meets collaboration.

Steam A - Biomarker and Companion Diagnostics Conference

Stream B - Next Gen Microbiome and Probiotics Conference

Stream C- Next Gen Immuno-Oncology Conference

Biomarker Discovery: Discussions on novel techniques and strategies for identifying new biomarkers, including genomics, proteomics, metabolomics, and bioinformatics.
Precision Medicine: The role of biomarkers in tailoring treatments to individual patients for better efficacy and reduced side effects.
Clinical Validation and Validation Strategies: Strategies for rigorously validating biomarkers for clinical use and addressing challenges in biomarker validation.
Clinical Applications of Biomarker: Cancer, Immunology, Neurodegenerative Disorders, Cardiovascular Biomarkers
Bioinformatics and Data Analysis: Workshops and sessions on the analysis of biomarker data, including machine learning and artificial intelligence approaches.
Biomarker-Based Diagnostics: Presentations on the development and commercialization of biomarker-based diagnostic tests and platforms.
Collaborations and Industry Partnerships: Sessions on fostering collaboration between academia, industry, and government agencies to advance biomarker research.

Exploring the Function of the Gut Microbiome and Modulation of Immune Cells
Role of human skin microbiome in precision health
Modulating the GI Microbiome with Live Biotherapeutic Product to Enhance Efficacy of Cancer Immunotherapy
Oral-Systemic Microbiome Connection and its Modulation
Modulating the Vaginal Microbiome for Women’s Health and Fertility
Mechanisms of Oncobiotic LBP candidate in Enhancing Cancer Immunotherapy
Microbiome as a science and its clinical applications- skin, gut & women’s health
Prebiotics, Probiotics and Postbiotics
Treating Clostridioides difficile: Microbiota-based Live Biotherapeutic Products to Provide the Answer
Microbiome’s role in Cancer

Preclinical and Translational Immuno-Oncology Developments
Next Gen Antibodies and Targeted Therapies
Immune Checkpoint Inhibitors and Combination Therapies
Tumor Microenvironment and Cancer Biomarkers
CAR-T cell therapy, T Cell Therapy, Adoptive Cell Therapy
Cancer Vaccines and Cancer Microbiome
Personalizing Cancer Treatment- Challenges and Opportunities

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson Jim Kean, Chief Executive Officer, Molecular You	08:55 - 09:00
BIOMARKER DRUG DISCOVERY AND ASSAY VALIDATION
Keynote Presentation : Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Ian Pike, Chief Scientific Officer, Proteome Sciences PLC	09:00 - 09:30
Spatial Analysis in Ulcerative Colitis and Crohn’s Disease Jiangwei Zhang, Senior Principal Scientist, Bristol Myers Squibb	09:30 - 10:00
Development of Methylation and Mutation Panel for Colorectal Cancer Collin Hudzik, Scientist, EpigenDx	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Next Gen Proteomics identified protein signatures for early pan cancer detection and stratification Kathy Nevola, Data Scientist, Olink	11:15 - 11:45
Flow cytometry for biomarker development, clinical trial assays, MRD, and CDx Scott J. Bornheimer, Associate Director, Medical & Scientific Affairs, BD Biosciences	11:45 - 12:15
AI and Multimoodal Biomarkers for Personalized Pain Medicine Carl Saab, Professor, Innovation Lead Digital Health, Cleveland Clinic	12:15 - 12:45
Identification of cancer cell surface target for antibody drug conjugate development. Ginette Serrero, CEO, Precision Antibody, A&G Pharmaceutical, Inc. \| Precision Antibody	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Role of biomarkers in personalized medicine Identifying Variants Associated with Creatinine and Cystatin C Serum Levels in the Top 1% of the Population Provides Insight into the Genetic Architecture of Kidney Function and Chronic Kidney Disease. Matteo D’Antonio, Assistant Professor, University of California, San Diego	14:15 - 14:45
Innovative oncology liquid biopsy testing in global markets, from lab testing to CDx Myles A. Walsh, Director of Business Development, Predicine	14:45 - 15:15
Microbial Marvels: Unleashing Targeted Drug Discovery with Pragma Bios Innovative Approach to Disease-Associated Small Molecules and Novel Biomarkers Kareem Barghouti, CEO, Pragma Bio	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
AI-powered multi-omic health analytics Jim Kean, Chief Executive Officer, Molecular You	16:30 - 17:00
Closing Remarks from the Chairperson	17:00 - 17:30
Drinks, Reception & Networking	17:30 - 17:30

Opening Remarks from the Chairperson Julius Goepp, CEO, Evimero	08:55 - 09:00
UNVEILING TOMORROW’S HEALTH WITH NEW MICROBIOME FINDINGS
Keynote Presentation : An Accurate Cost Effective Long Read Solution Using Short Read NGS Platforms for Microbiome Research and Discovery. Ming Lei, President and CEO, Universal Sequencing Technology	09:00 - 09:30
Taxonomy- and Disease Agnostic Approach to Microbiome Therapeutics Julius Goepp, CEO, Evimero	09:30 - 10:00
Development of human primary cell-culture derived mucus to support microbiome research Niki Heinz, Sr. Director of Business Development, , Altis Biosystems	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Oral-Systemic Microbiome Connection and its Modulation Emily Stein, CEO, Primal Health Inc.	11:15 - 11:45
What is in Your Bottle? Dana Buckman, CEO, BioForm Solutions	11:45 - 12:15
Biocalorimetry, the science behind the calScreener™, is revolutionizing the way companies approach the development of probiotics. This technology simplifies the study of complex interactions, conserves valuable time and resources in screening, and can be instrumental in ensuring product safety and efficacy. The calScreener™ has demonstrated high value in media optimization for probiotic production, and providing phenotypic readouts in opaque and complex growth media. Its key benefits include rapid analysis, non-destructive assay, and the ability to run any type of media. It offers direct metabolism measurement from single and multi-species cultures, and activity yield, setting a new standard in the field. Katrin Beilharz, Technical Marketing Specialist, Symcel	12:15 - 12:45
Next-Generation Probiotics Against Enteric Pathogen Infection and Chronic Inflammatory Disease Arun K. Bhunia, Professor of Food Microbiology, Chair, Interdepartmental Food Science Graduate Program, Department of Food Science, Purdue Institute of Inflammation, Immunology and Infectious Disease	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
REVOLUTIONIZING WELLNESS – EXPLORING THE FUTURE OF MICROBIOME AND PROBIOTICS
How Lifestyle and Life Stages affect Gut Microbiota and the power of Biotics. Miguel Freitas, Vice President - Scientific Affairs, Danone	14:15 - 14:45
Effect of Back to Health - An Evolutionary Biology Perspective on the Skin Microbiome Larry Weiss, Chief Executive Officer and Founder, Symbiome	14:45 - 15:15
Working with live probiotics – insights in developing effective skincare products from formulator’s perspective Maya Ivanjesku, Chief Scientific Officer, M2B Pharma	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Synbiotics for Human Health – Opportunities and Challenges Vandana Sharma, Principal Nutrition Scientist, Pharmavite	16:30 - 17:00
Closing Remarks from the Chairperson Julius Goepp, CEO, Evimero	17:00 - 17:30
Drinks Reception & Networking	17:30 - 17:30

NEW ANTIBODIES DEVELOPMENT AND TUMOR MICRO-ENVIRONMENT
Keynote Presentation – Identification of potential patient selection biomarkers for the treatment of cancer with tivumecirnon (FLX475) in combination with anti-PD-1 Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics	08:55 - 09:50
Nu.Q® Discover – Quantitative nucleosome biomarker profiling of the tumour microenvironment Mark Eccleston, Founder and Chief Technology Officer, Volition Eric Ariazi, Distinguished Translational Medicine Scientist, Volition	09:50 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:20
Case Studies Leveraging 20,000 Digitized IO KM Curves– Interactive Analysis and Real-Time Insights at the Forefront of Immuno-Oncology Bruno Larvol, Founder & CEO, LARVOL	11:20 - 11:55
Advancing the Immuno-Oncology Pipeline with Humanized Mice Dan Georgess, Chief Scientific Officer, TransCure bioServices,	11:55 - 12:30
Veracyte Biopharma Services, your trusted partner for biomarker testing for spatial proteomics, transcriptomics, and genomics Valerie Balme, Associate Director, Business Development, Veracyte	12:30 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:20
BioMice: Preclinical Oncology/Immuno-Oncology Models for Evaluating Novel Therapeutics in Vivo Jay Zhang, Sr. Business Development Manager, Biocytogen	14:20 - 15:00
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Ian Pike, Chief Scientific Officer, Proteome Sciences PLC	15:00 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Engineered nanomaterial-mediated systemically administered m-RNA-based gene therapy directed exclusively to cancer, present successes and future prospects. A. C. Matin, Professor of Microbiology & Immunology, Emeritus , Stanford University School of Medicine	16:30 - 17:00
Closing Remarks from the Chairperson	17:00 - 17:30
Drinks Reception & Networking	17:30 - 17:30

Registration

08:15 - 09:00

Welcome note from MarketsandMarkets

09:00 - 09:05

FROM BIOMARKERS TO CDx: STRATEGIES TO ACCELERATE CDx DEVELOPMENT AND COMMERCIALIZATION
Opening Remarks from the Chairperson Jim Kean, Chief Executive Officer, Molecular You	09:05 - 09:10
Keynote Presentation Bringing AI to Companion Diagnostics Ken Bloom , Head of Pathology, Nucleai	09:10 - 09:45
The crucial role of biospecimen management in precision medicine Ayat Alsaraby, Sr. Manager, Clinical Biomarker, Repare Therapeutics	09:45 - 10:20
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:20 - 11:05
Opportunities for biomarker development in neuroscience Pablo Lapuerta, Chief Executive Officer, 4M Therapeutics Inc.	11:05 - 11:40
Identifying underlying mechanisms of neurological conditions with multi-omic biomarker analysis Rob Fraser, Chief Scientific Officer, Molecular You	11:40 - 12:15
Panel Discussion: Biomarker Revolution: Enhancing Patient Care Across Specialties Nicole Miller, Vice President, Molecular Diagnostics Global Medical Affairs, Ultragenyx Ken Bloom , Head of Pathology, Nucleai Julius Goepp, CEO, Evimero Pablo Lapuerta, Chief Executive Officer, 4M Therapeutics Inc.	12:15 - 13:00
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:00 - 13:30
END OF CONFERENCE	13:30 - 13:30

Opening Remarks from the Chairperson Julius Goepp, CEO, Evimero	09:05 - 09:10
CULTIVATING WELLNESS: PIONEERING THE FUTURE OF MICROBIOME AND PROBIOTICS
Keynote Presentation: Functional Food & The Microbiome, Mitochondria Axis Christopher Damman, Associate Professor of Gastroenterology, University of Washington	09:10 - 09:45
Implementation of Metaproteomics approaches for characterizing the dynamic metabolic activities in human gut microbiomes. Robert Hettich, Distinguished Research Scientist \| Leader-Bioanalytical Mass Spectrometry Group of the Biosciences Division, Oak Ridge National Laboratory	09:45 - 10:20
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:20 - 11:05
Metabolic Characterization of Microbial Communities Peter Karp, Technical Director of the Bioinformatics Research Group, , SRI International	11:05 - 11:40
Developing microbiome-powered treatments for chronic skin conditions Lada Rasochova, CEO, Dermala	11:40 - 12:15
May the Fiber Be with You: Gut Microbiomes from a remote Amazon village to the undergraduate lab Kathrine Whiteson, Associate Professor, Irvine University of California, Irvine and co-Director, UCI Microbiome	12:15 - 12:45
Panel Discussion: Emerging Technologies in Microbiome & Probiotics Marina Santiago, Director of Strategic Projects, mbiomics Maya Ivanjesku, Chief Scientific Officer, M2B Pharma Larry Weiss, Chief Executive Officer and Founder, Symbiome	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 13:30
END OF CONFERENCE	13:30 - 13:30

Opening Remarks from the Chairperson Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics	09:05 - 09:10
PRECLINICAL AND TRANSLATIONAL IMMUNO-ONCOLOGY UPDATES- NEW CHECKPOINTS FOR IO
Rapid discovery and screening of truly human biologics Wyatt McDonnell, Co-Founder, CEO, and Chairman of the Board of Directors, Infinimmune	09:10 - 09:45
Mechanistic insights into PD-1 action-translational and clinical data. Adil Daud, Director, Melanoma Program, UCSF Medical Center	09:45 - 10:20
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:20 - 11:05
Spatial Analytics of the TME and Discovering Spatial Biomarkers for Immunotherapy Arvind Rao, Associate Professor of Computational Medicine and Bioinformatics, Department of Computational Medicine and Bioinformatics, University of Michigan Ann Arbor	11:05 - 11:40
Developments in car-t and t-cell therapies personalized immunotherapy Preclinical Data for Novel Oncolytic Agent and its Ability to Pair with Immune Checkpoint Blockade Matt Giacalone, CEO, Vaxiion Therapeutics	11:40 - 12:15
Panel Discussion: Clinical Applications of Biomarkers in Immuno-Oncology, Immunology, Neurology, and Inflammatory Diseases Jack Chen, Scientific Director, Immuno-Oncology, Precision Medicine, AbbVie Rob Fraser, Chief Scientific Officer, Molecular You Wyatt McDonnell, Co-Founder, CEO, and Chairman of the Board of Directors, Infinimmune	12:15 - 13:00
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:00 - 13:30
END OF CONFERENCE	13:30 - 13:30

SPEAKERS

Christopher Damman

Associate Professor of Gastroenterology, University of Washington

Nur Hasan

Chief Executive Officer, EzBiome Inc

A. C. Matin

Professor of Microbiology & Immunology, Emeritus , Stanford University School of Medicine

Paul Kassner

Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics

Dana Buckman

CEO, BioForm Solutions

Jim Kean

Chief Executive Officer, Molecular You

Adil Daud

Director, Melanoma Program, UCSF Medical Center

Pablo Lapuerta

Chief Executive Officer, 4M Therapeutics Inc.

Arun K. Bhunia

Professor of Food Microbiology, Chair, Interdepartmental Food Science Graduate Program, Department of Food Science, Purdue Institute of Inflammation, Immunology and Infectious Disease

Maya Ivanjesku

Chief Scientific Officer, M2B Pharma

Vandana Sharma

Principal Nutrition Scientist, Pharmavite

Ian Pike

Chief Scientific Officer, Proteome Sciences PLC

Marina Santiago

Director of Strategic Projects, mbiomics

Antonio Gomes

Principal Scientist, Xbiome

Kevin Roelofs

Principal Consultant, Greenbeard Consulting LLC

Carl Saab

Professor, Innovation Lead Digital Health, Cleveland Clinic

Robert Hettich

Distinguished Research Scientist | Leader-Bioanalytical Mass Spectrometry Group of the Biosciences Division, Oak Ridge National Laboratory

TBA, Senior Representative, Biocytogen

Bruno Larvol

Founder & CEO, LARVOL

TBA, Senior Representative, Elucidata

Senior Representative, Elucidata

Ginette Serrero

CEO, Precision Antibody, A&G Pharmaceutical, Inc. | Precision Antibody

Zachery Lewis

Principal Consultant, Lewpine Consulting

Leena Gandhi

Chief Medical Officer, NextPoint Therapeutics

Mark Eccleston

Founder and Chief Technology Officer, Volition

Rob Fraser

Chief Scientific Officer, Molecular You

Ming Lei

President and CEO, Universal Sequencing Technology

Eric Ariazi

Distinguished Translational Medicine Scientist, Volition

Myles A. Walsh

Director of Business Development, Predicine

Sahil Khanna

Professor of Medicine, Chair GI Hospital Practice, Associate Program Director Internal Medicine Residency Program, Medical Director Desk and Secretarial Operations, Mayo Clinic

Matt Giacalone

CEO, Vaxiion Therapeutics

Jiangwei Zhang

Senior Principal Scientist, Bristol Myers Squibb

Kareem Barghouti

CEO, Pragma Bio

Julius Goepp

CEO, Evimero

Kathy Nevola

Data Scientist, Olink

Mikael Barmore

VP Biopharma Business Development, Veracyte

Miguel Freitas

Vice President - Scientific Affairs, Danone

Collin Hudzik

Scientist, EpigenDx

Jack Chen

Scientific Director, Immuno-Oncology, Precision Medicine, AbbVie

Matteo D’Antonio

Assistant Professor, University of California, San Diego

Larry Weiss

Chief Executive Officer and Founder, Symbiome

Kathrine Whiteson

Associate Professor, Irvine University of California, Irvine and co-Director, UCI Microbiome

Katrin Beilharz

Technical Marketing Specialist, Symcel

Arvind Rao

Associate Professor of Computational Medicine and Bioinformatics, Department of Computational Medicine and Bioinformatics, University of Michigan Ann Arbor